No, that's exactly what he didn't say in March. W
Post# of 154232

Quote:
The Company continues to be on track financially and we forecast sufficient cash and drug supply on hand to advance our clinical priorities in 2025. As we approach key milestones and announcements in the coming months, we’ll evaluate opportunities to raise additional funds at optimal times and through methods that best serve the Company and its shareholders.
Which mean, first, that they have the cash for 2025. And what they might do is raise additional funds by methods that serve the shareholders -- i.e., which do not dilute our holdings. This could be by bringing in licensing or partnership fees -- otherwise the mention of announcements and key milestones doesn't mean anything. He means we'll make announcements and then raise funds by methods that HELP the share price, not dilute it. He is not talking about a market raise.

